Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma

Improved insight into the molecular and genetic profile of different types of epithelial ovarian cancer (EOC) is required for understanding the carcinogenesis of EOC and may potentially be exploited by future targeted therapies. The aim of the present study was to identify a unique microRNA (miRNA) patterns and key miRNAs, which may assist in predicting progression and prognosis in high-grade serous carcinoma (HGSC) and clear cell carcinoma (CCC). To identify unique miRNA patterns associated with HGSC and CCC, a miRNA microarray was performed using Chinese tumor bank specimens of patients with HGSC or CCC in a retrospective analysis. The expression levels of four deregulated miRNAs were further validated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in an external cohort of 42 cases of HGSC and 36 cases of CCC. Kaplan-Meier analysis was performed to analyze the correlation between the expression levels of the four miRNAs and patient prognosis. Among these validated miRNAs, miR-510 was further examined in another cohort of normal ovarian tissues, as well as the HGSC, low-grade serous carcinoma (LGSC) and CCC specimens using RT-qPCR and in situ hybridization. The results revealed that, of the 768 miRNAs analyzed in the microarray, 33 and 50 miRNAs were significantly upregulated and downregulated, respectively, with at least a 2-fold difference in HGSC, compared with CCC. The quantitative analysis demonstrated that miR-510 and miR-129-3p were significantly downregulated, and that miR-483-5p and miR-miR-449a were significantly upregulated in CCC, compared with HGSC (P<0.05), which was consistent with the microarray results. Kaplan-Meier analysis revealed low expression levels of miR-510 and low expression levels of miR-129-3p, advanced International Federation of Gynecology and Obstetrics (FIGO) stage, lymphatic metastasis and that HGSC was significantly associated with the poorer overall survival rates (P<0.05). The expression of miR-510 was significantly higher in the LGSC and CCC tissues, compared with the HGSC and normal ovarian tissues. The results of the present study suggested that different subtypes of EOC have specific miRNA signatures, and that miR-510 may be involved differently in HGSC and CCC. Thus, miR-510 and miR-129-3p may be considered as potential novel candidate clinical biomarkers for predicting the outcome of EOC.

[1]  Dan Han,et al.  MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma , 2013, Tumor Biology.

[2]  Elizabeth Swisher,et al.  MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features , 2012, World Journal of Surgical Oncology.

[3]  X. Qin,et al.  miRNA expression profile in primary gastric cancers and paired lymph node metastases indicates that miR-10a plays a role in metastasis from primary gastric cancer to lymph nodes. , 2012, Experimental and therapeutic medicine.

[4]  N. Matsumura,et al.  Recent Concepts of Ovarian Carcinogenesis: Type I and Type II , 2014, BioMed research international.

[5]  Yanchun Ding,et al.  Synchronous detection of miRNAs, their targets and downstream proteins in transferred FFPE sections: applications in clinical and basic research. , 2012, Methods.

[6]  Chang-Zheng Chen,et al.  MicroRNAs as oncogenes and tumor suppressors. , 2005, The New England journal of medicine.

[7]  Hong-Fei Wu,et al.  A Ten-MicroRNA Signature Identified from a Genome-Wide MicroRNA Expression Profiling in Human Epithelial Ovarian Cancer , 2014, PloS one.

[8]  Tadashi Kimura,et al.  The Role of MicroRNAs in Ovarian Cancer , 2014, BioMed research international.

[9]  Shivani R. Kandukuri,et al.  FIGO 2013 staging system for ovarian cancer: what is new in comparison to the 1988 staging system? , 2015, Current opinion in obstetrics & gynecology.

[10]  Ben Davidson,et al.  Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker , 2014, BMC Cancer.

[11]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[12]  L. De Cecco,et al.  Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients , 2011, Oncotarget.

[13]  R. Kurman Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  David P Turner,et al.  MicroRNA-510 promotes cell and tumor growth by targeting peroxiredoxin1 in breast cancer , 2012, Breast Cancer Research.

[15]  R. Zeineldin,et al.  Novel nanotechnology approaches to diagnosis and therapy of ovarian cancer. , 2011, Gynecologic oncology.

[16]  Wei Zhu,et al.  A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth , 2012, Oncogene.

[17]  S. Knudsen,et al.  Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. , 2010, Cancer research.

[18]  A. Jemal,et al.  Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[19]  S. Rosenwald,et al.  Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. , 2009, Gynecologic oncology.

[20]  A. Scorilas,et al.  Downregulation and prognostic performance of microRNA 224 expression in prostate cancer. , 2013, Clinical chemistry.

[21]  Andrea Ventura,et al.  MicroRNAs and Cancer: Short RNAs Go a Long Way , 2009, Cell.

[22]  D. Aoki,et al.  Application of MicroRNA in Diagnosis and Treatment of Ovarian Cancer , 2014, BioMed research international.

[23]  Artemis G. Hatzigeorgiou,et al.  Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer , 2008, Proceedings of the National Academy of Sciences.

[24]  E. Oliva,et al.  Clear cell carcinoma of the ovary: evaluation of prognostic parameters based on a clinicopathological analysis of 100 cases , 2015, Histopathology.

[25]  C. Gilks,et al.  Ovarian carcinoma pathology and genetics: recent advances. , 2009, Human pathology.

[26]  Brock A. Humphries,et al.  MicroRNAs: Novel Players in Cancer Diagnosis and Therapies , 2014, BioMed research international.

[27]  P. Sadłecki,et al.  Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer , 2013, International journal of endocrinology.

[28]  E. Berns,et al.  MicroRNAs in ovarian cancer biology and therapy resistance. , 2010, The international journal of biochemistry & cell biology.

[29]  A. Godwin,et al.  Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management , 2009, Molecular oncology.

[30]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[31]  Sheila M. Reynolds,et al.  Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. , 2013, Cancer cell.

[32]  Anil K Sood,et al.  Early events in the pathogenesis of epithelial ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.